ZOE has raised $87.0M in total across 5 funding rounds.
ZOE's investors include Accomplice, Coefficient Capital, Partech Ventures, Eli Manning, Errol Damelin, Pascal Gauthier, Tim Kendall, Bennu, Coatue, Crosslink Capital, Dreamers VC, General Catalyst.
ZOE is a London-based health technology company specializing in personalized nutrition by leveraging scientific research, artificial intelligence (AI), and microbiome metagenomics to provide tailored dietary recommendations. It serves individuals seeking to improve their health and well-being through data-driven insights into their unique metabolism and gut microbiome. ZOE’s flagship product is a personalized nutrition program that combines at-home biological testing with AI-powered analysis to deliver actionable food scores and expert advice, helping users optimize their diet and overall health. The company has demonstrated strong growth momentum, with over 100,000 members benefiting from its program and its research published in leading journals such as *Nature Medicine*[1][2][3][4].
Founded in 2017, ZOE originated as a spin-out from King’s College London, driven by the belief that novel digital technologies could enable unprecedented depth and scale in human health research. The founders and leadership, including Wolf, former chief product officer at Criteo, brought expertise in scaling technology businesses. The idea emerged from large-scale nutritional studies, notably the PREDICT program, which is the world’s largest in-depth nutrition research initiative. Early pivotal moments include the pivot during the COVID-19 pandemic to launch the ZOE COVID Study app, which provided valuable data and insights during the crisis, demonstrating the company’s agility and scientific rigor[1][2].
ZOE rides the growing trend of personalized, data-driven health and nutrition, leveraging advances in AI, digital health, and microbiome science. The timing is favorable due to increasing consumer demand for individualized health solutions and the rise of preventive healthcare. Market forces such as rising chronic disease prevalence and the shift from one-size-fits-all dietary advice to precision nutrition support ZOE’s mission. By integrating large-scale biological data with AI, ZOE influences the broader ecosystem by setting new standards for personalized health interventions and demonstrating the commercial viability of science-driven nutrition tech[1][2].
ZOE is well-positioned to expand its impact as personalized nutrition gains mainstream acceptance. Future growth will likely be shaped by continued advances in AI, expanding biological datasets, and integration with broader digital health platforms. The company’s commitment to rigorous science and user-centric design suggests it will remain a leader in the personalized health space. Over the next decade, ZOE aims to catalyze a shift toward long-term, tech-enabled health improvement, potentially inspiring a new wave of companies that blend science and technology to enhance human well-being[1].
ZOE has raised $87.0M across 5 funding rounds. Most recently, it raised $15.0M Series B in July 2024.
